SINGAPORE, April 28, 2014 /PRNewswire/ -- Moleac, a revenue-generating Biopharma company focused on stroke recovery, announced today the appointment of Mr Elmar Schnee as non-executive Chairman of the company.
Elmar Schnee succeeds to Prof Marc Vasseur, co-founder of Moleac and first Chairman (2004-2013).
Mr. Schnee was from 2011 - 2013 CEO of Cardiorentis in Zug, Switzerland. Prior to this, Mr. Schnee was General Partner and member of the Executive Board of Merck KGaA, responsible for its worldwide pharmaceutical business in Rx and OTC with sales of € 6 Billion and 18,000 employees until June 2011. He also led the major restructuring of the business in acquiring Serono for € 10.3 billion and selling the Generic Division for € 4.9 billion. Mr. Schnee led the successful integration into Merck Serono as CEO until end of 2010.
Mr. Schnee joined Merck KGaA in 2003 as President for France. He was promoted to Head of Global Ethical Pharmaceuticals and in 2005 elected as General Partner and Member of the Executive Board.
Prior Mr. Schnee held senior roles in Marketing, Strategy and Business Development in UCB Brussels, Sanofi-Synthelabo in Paris, Migliara Kaplan in Baltimore and Fisons in UK.
Mr. Schnee is currently a Director of Gentium SpA, Cardiorentis AG and Anecova SA.
Elmar Schnee said:
"I am very excited to join Moleac as Chairman and work together with the board and management to further develop NeuroAiD. Moleac has unique knowledge in the area of stroke recovery and NeuroAiD has proven already its utility in supporting stroke patients recovering faster and better. There is a great need for new drugs supporting stroke patients and I recognise the potential of Moleac to develop new drugs in this high need indication."
David Picard CEO of Moleac said:
"Moleac has provided already a therapeutic solution to thousands of stroke survivors with NeuroAiD. It now aims to deliver a stroke treatment which will enable an even larger number of patients to benefit from its knowhow. We welcome the wide experience that Elmar brings to Moleac in pharmaceutical development and operations, to take Moleac through the second stage of its rapid development to answer the needs of the stroke sufferers."
Moleac is a biopharmaceutical company founded in 2003 in Singapore, dedicated in finding and developing new medicines for the unmet needs of patients worldwide. Its development model combines a modern clinical approach and the latest biotechnologies.
NeuroAiD™ is the first stroke treatment that helps patients recover faster and a better from stroke disabilities while combined to a rehabilitation program. NeuroAiD™ is derived from natural components, carefully selected for their efficacy and safe use. It currently reaches out to patients in over 25 countries.
For further information, please contact Olfa Khechine, Global Marketing Manager, Moleac Singapore
Tel: (+65) 6211 3710 - Ext. 124
Email: [email protected]